India M&A Trends: Rational Valuations, Foreign Firms Shed Products
This article was originally published in PharmAsia News
Rational valuations and the potential divestment of older portfolios by foreign firms were some of the key mergers and acquisitions (M&A) trends highlighted by industry experts at a recent congress in India.
You may also be interested in...
Private equity firms partnering with senior management professionals bitten by the entrepreneurial bug to buy pharmaceutical businesses in India were some of the emerging trends highlighted by experts at a recent CPhI congress in Mumbai. Scrip covers the key conference highlights on the "maturing" Indian M&A market, including how foreign firms are shedding their older portfolios to reallocate resources to newer products.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.